quarter product volumes X% David, In starting slide of consecutive third Find which as year-over-year, resulting reported seventh in good represents, year-over-year, on the Thanks, and prices volume X% net mentioned, declined quarter, XX. by growth. the Bob by afternoon X%. everyone. information selling declining sales grew Net sales
outlook in for base addition business We and expect growth our stable we revenue have year. next of anticipated a the Otezla, with XXXX
starting from Recall as repeat driven as Now Prolia experiences trends. with increasing rates another let rates. details strong product Prolia by year-over-year, growth coming of Prolia growth volume seasonal XX% me delivered with that consistent new share on slide quarter some XX. well strong patient
launch occur every That's osteoporosis sequentially. fractures as The which solid Worldwide as a X.X doubled osteoporosis three community sales EVENITY million than fracture the to therapy recognized a a of more start to by been innovative year. each seconds. due has is off highly
X fracture to In believe We there and are one million within osteoporosis-related risk an two at is these who of having important fracture to the had have offer greatest patients EVENITY approximately U.S., patients. are an the next years. another option
an us a permanent solid foundation on a reimbursement we've in has strategy. to majority will Otezla the adding Japan, should expansion Within ability been we represents sales, uptake. EVENITY upon EVENITY J-code, which Japan of U.S., and creates anticipate that currently uptake give the In which international encouraging. deliver received our facilitate very which
year-over-year to Worldwide the by Next growth sales be to Repatha leader the we PCSKX by U.S. continue QX as on unit slide was Class. XX% on driven XX. grew XX% of year-over-year, the market
New-to-brand U.S. prescriptions at XX% improving, year-over-year. are steadily growing
LDL with a stroke. cardiovascular that pleased today. remains still XX helping the suffer in disease we're year our common is Although, use to globally cholesterol, a Every in heart the society fact of will million too growing or Repatha people lower much attack
which out lower in professional the XX less in means prior recently, Cardiology milligrams the milligrams cardiovascular societies, the have less levels cardiovascular as Oncology U.S. most LDL-C of Heart patients recognized per increasingly in with and event lowering the American in and to seven European high-risk The disease the including Society elevated cardiology Approximately XX of treatment. recommends deciliter of adults lipid-lowering of patients LDL-C events. despite by with adults levels importance per is risk of Association, XX optimal than American deciliter than high-risk now two cardiovascular Cardiology LDL-C a
factor play patients is role this addressed. their Removing inhibitors use health barriers ensuring objective. Repatha PCSKX helping crisis important can for a in achieve like cholesterol-lowering PCSKX in is effectively critical an
is just the In year. only from plans pleased now access XX% U.S., that's XX% commercial we're require A and improving. up that last attestation of physician
in increased of majority to removing for which rates mandates, from moving Repatha specialty prescriptions. patients pharmacies, are Overall, U.S., more improved meaningfully. XX% plans retail and commercial Medicare has approval the the now more fill Additionally, to Repatha XX% a abandonment pharmacy rate accessible
and in who Affordability of is than an co-pay Medicare of all have prescribed affordable less will Repatha patients $XX. for Medicare patients half a approximately XXXX are concern
of and in the declined blended the in contracting of the year, QX, Repatha, advent available price to over Although, longer selling December was access U.S. previous XXXX. be due stable list With net lower-list-price better versus XXXX for net the lower-list-price relatively prescriptions, now partly no will the total with the Repatha for price sequentially. price Repatha SKU XX% effective representing partly XX sale original of of
accounting on by primarily proportion unit quarter-over-quarter due than reported coming Aimovig a These from On sales XX. result million adjustments for of declined business in our to to anticipated. of the basis sales slide net grew volume $XX a periods. although prior in initially from unfavorable estimates on XX%, lower-priced Now XX%, changes population Medicaid discounts higher paid
reminder, demonstrating business. are early we of the significant accounting price market. Aimovig $XX changes are variability treatment, XXXX, potential estimates and has there Considering a of penetrate reported source net favorable U.S. in to patients migraine million of QX As million CGRP the this of remaining impact on X who in eligible for in
patients a been CGRP approximately prescribed patient X,XXX have and Each starts than week more therapy XXX,XXX Aimovig. date to
market physicians primary XX,XXX QX. total the Additionally, prescribed have increasing XX,XXX with of XX% care exiting prescribers launch, more prescribers. Aimovig now than consistently since is including the leader of Aimovig prescriptions number is as
pleased see transition is from nicely QX demand XX% we're free the XX% of of program patients drug to the to to pricing, end QX. increasing Regarding in paid from progressing our at
CVS our our recent strong agreement Caremark Additionally, out access into rounds going position XXXX. with
oncology and again year-over-year growing billion of The collectively double by digits the hematology six our at XX% totaled portfolio business. quarter, a to $X.X brands on in basis. Moving
As in by XX% within for year-over-year, larger volume. grew QX portfolio, driven the this some of XGEVA brands
NCCN XGEVA's over guidelines indication. in status the cancer, reminder XGEVA a As prostate in with castration-resistant this zoledronic recognize preferred acid superiority reinforcing
prescribers primarily KYPROLIS continuing grew breadth driven year-on-year, volume the XX% XX% growth increase. to by of with
Dave as growing behind add KYPROLIS treatment in body CANDOR to the myeloma, recent KYPROLIS' the to study you'll clinical this of demonstrating more hear evidence the and from multiple role invest results Reese. important And the continue indicate. of of We on
included of sales accounting estimates increased Moving estimates on competition. year-over-year, accounting to increases declines benefit offset driven continued to QX by X% in unit net volume of related by X% due changes million to Sales approximately a results in and in in selling Enbrel. $XX price changes discounts.
Enbrel full We're rheumatoid from from device, feedback net the price year anticipate we to in investments positive arthritis Overall, selling modest making with patients. volume on AutoTouch to while Mini XXXX. product, basis continues multi-use which ENBREL a a expect trends including a we continue benefit receive in
ABP behind of as which substantially R&D biosimilars which Enbrel's inflammation has strengthened reaffirmation of pending asthma investing Otezla; pipeline. our property; our other to number assets REMICADE; earlier of We're for is intellectual of of AMGEVITA the portfolio, been a our by and our well addition potential that tezepelumab XXX, biosimilar are as the the in
on on to in Neulasta Now volume more with on slightly in the basis. brands XX. XX% XX% with was decline In share declined comparable to segment just some XX% our Exit the U.S. unit QX QX, of sales declining under the mature in Neulasta of a Onpro year-over-year sequential U.S. long-acting slide a
services. have timing in of along broader space. competitors sometime but performed could commercial the the the anticipate We our reflecting We're the our launch is encouraged our and customers has so that the and additional the in how future, by supply U.S. well reliability molecules of the quality uncertain confidence in complexity developing Onpro manufacturing with demonstrating in far that
recall that benefited QX we Looking order of million a forward do $XX anticipate repeating XXXX BARDA this from quarter. not that
Finally, outside competition. increasing Neulasta due declined of U.S., XX% to the
declined of function XX. with is Switching XX% year-over-year driven selling by to increased net X% Meanwhile volume sales nephrology to on declined DaVita. QX QX our due a lower to price, commitments pricing competition. slide lower which EPOGEN due starting in contractual Aranesp
long-acting in expect rate to to a U.S. the and sales with Aranesp faster competition at short-acting continue both We decline
Turning to XX. Sensipar on slide
declined the $XXX at-risk for million some quarter. launches of year-over-year result to a XX% sales generic As
of about the magnitude proceedings Given sales. Sensipar U.S. future legal there the an remains uncertainty ongoing
quarter. by Parsabiv XX% third the in grew
of and As a trends for and larger already a included On patterns, reminder, Parsabiv FMC providers independent purchasing a dialysis slowly DaVita utilize are calcimimetic midsized majority QX. their quarter-over-quarter in adoption. impacted by a were while patients which purchase basis, increasing
and QX XX. million of $XXX sales Our biosimilars noted recorded on slide in are
Our in come launches two successful fruition in launches two U.S. biosimilar Europe strategy recent and with continues to the to
U.S. MVASI importance already U.S. in commercial of KANJINTI KANJINTI a result continued with are customers outside is annualizing $XXX and AMGEVITA our of growth The quality adoption well as as of supply Amgen's the million sales global and and the uptake and and chain Our capabilities the services. approximately at recognizing of
along presence the while system, Our health experience a for established a in help return in in model. commercializing areas to innovative our generating existing therapeutic also these with costs us with to products commercial resources reduce factors productive operating shareholders. care provides These
When looking of good Medicare in terms accounts. and coverage making accounts commercial progress we attained success access, majority at factors U.S. in are in the have for national of in the
As of this and reimbursement uptake. MVASI a be received for both KANJINTI and further codes will for we've QX, believe catalyst
we're continue in adoption of at When looking encouraging differences the seen acceleration. while prescribers, non-XXXB uptake to clinic of markets hospitals between rates important terms the segment is in in showing Outside very signs price and products adoption erosion. we U.S., see
larger experiencing a markets while and more at opportunity. markets, including Some exhibit sustainable uptake pricing strong more other and discounted Germany are France levels, balanced
we're patients again, brands expertise we defending volume In Otezla. our uptake products, oncology, nicely to footprint our AMGEVITA while and of benefit better care continue from and our launched while and will to the system. plan recently to mature with more able deliver of Here drive leverage the health summary, addition to in for outcomes synergize
to Now Reese. let me Dave turn over
